Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases.
The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease.
Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; CABA-201, a 4-1BB-containing CD19-CAR T investigational therapy, for the treatment of severe autoimmune diseases; PLA2R-CAART, a discovery stage product to treat patients with PLA2R-associated membranous nephropathy; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris.
It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia.
The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018.
Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 15, 24 | -0.51 Decreased by -13.33% | -0.48 Decreased by -6.25% |
| Mar 21, 24 | -0.46 Increased by +11.54% | -0.39 Decreased by -17.95% |
| Nov 9, 23 | -0.37 Increased by +5.13% | -0.40 Increased by +7.50% |
| Aug 10, 23 | -0.37 Increased by +17.78% | -0.44 Increased by +15.91% |
| May 11, 23 | -0.45 Increased by 0.00% | -0.48 Increased by +6.25% |
| Mar 16, 23 | -0.52 Decreased by -6.12% | -0.45 Decreased by -15.56% |
| Nov 10, 22 | -0.39 Increased by +13.33% | -0.48 Increased by +18.75% |
| Aug 11, 22 | -0.45 Increased by 0.00% | -0.50 Increased by +10.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0.00 Decreased by N/A% | -16.45 M Decreased by -48.50% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -14.49 M Decreased by -13.53% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -14.75 M Decreased by -14.42% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -14.88 M Decreased by -7.14% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -11.08 M Increased by +4.19% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by -100.00% | -12.76 M Decreased by -14.55% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -12.89 M Decreased by -32.89% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -13.89 M Decreased by -49.19% | Decreased by N/A% Decreased by N/A% |